Sanofi’s Dengue Vaccine Is Effective in Study – WSJ.com

The vaccine could still fail in further testing. Sanofi is conducting additional trials involving another 31,000 people in 10 countries in Latin America and Asia. The vaccine uses weakened forms of the dengue virus to raise the body’s immune response, a type of inoculation known as a “live attenuated vaccine.”

If Sanofi’s vaccine does make it to market, the company will be able to produce about 100 million doses a year at a factory in France—enough for about 33 million children, since each child requires three doses, Sanofi spokesman Pascal Barollier said Wednesday. The WHO estimates there are currently between 50 million and 100 million new dengue infections world-wide each year.

via Sanofi’s Dengue Vaccine Is Effective in Study – WSJ.com.

Advertisements


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s